INTRODUCTION
Sepsis has been used to describe the dynamic and often life-threatening systemic host response to infection. For centuries, physicians have sought for clues to curb the burden of disease. In 1841, the Austrian physician Ignaz Semmelweiss observed, 'The fingers and hands of students and doctors, soiled by recent dissections, carry those death-dealing cadaver's poisons into the genital organs of women in childbirth'. From this astute observation, protocols for proper hand hygiene were developed in his local maternity ward and fetal deaths from sepsis dropped from 16 to 3% [1] .
Today, sepsis remains a leading cause of death worldwide and has an incidence between 75 and 300 per 100 000 [2, 3] . In the USA, the economic burden of sepsis is astounding. Nearly $24 billion dollars are spent annually on septic patients with an increasing trend [4] . Sepsis alone carries a 25% mortality rate, but when combined with organ failure, this mortality rate doubles [3] .
Currently, much attention has been focused on the inflammatory host response in sepsis. Indeed, septic patients exhibit several biological markers for inflammation that often precede organ failure, providing a causal relationship between the two [5] . The inflammatory response to infection may ultimately serve as a protective mechanism against microbial invasion; however, when grossly exaggerated, inflammation can lead to multisystem organ dysfunction (MODS). Inflammation and disturbances in coagulation are inseparably tied, with each acting as a positive feedback for the activation of the other [6] . Coagulation abnormalities are nearly universal in septic patients and likely play a key role in MODS [7 && ]. The coagulopathy of acute sepsis (CAS) varies from overt thromboembolic disease to microvascular fibrin deposition. In severe cases, fulminant disseminated intravascular coagulation (DIC) presents with both thrombosis and diffuse hemorrhage.
CAS is likely driven by the derangements of multiple pathways versus a single mediator, which explains why many singe therapies have failed to improve the outcomes [4] . This review will discuss the pathogenesis of coagulopathy in acute sepsis and how it relates to MODS. It will also focus on tools to measure coagulation status and possible therapeutic interventions.
MEASUREMENT OF COAGULATION IN SEPSIS
Measurement of the coagulation disturbances in acute sepsis is a complex and time-sensitive endeavor that is best interpreted through serial measurements. Classical coagulation laboratory tests (CCTs) such as prothrombin time (PT), partial thromboplastin time, and fibrinogen have several limitations. First, plasma-based testing of coagulation eliminates the platelet contribution to thrombosis. Platelets actively contribute to thrombosis by providing a surface for thrombin generation and recruiting clotting factors that propagate the coagulation system [8] . CCTs do not reflect in-vivo blood coagulation and do not provide qualitative or functional data. Alternatives to CCTs such as measurement of natural anticoagulants, markers of fibrinolytic activity, and molecular markers of DIC are not routinely available, are not validated to specific disease patterns, and may not be practical in the clinical setting. Classical laboratory tests generally suffer from the same downfall: high sensitivity with low specificity (see list below). Classical coagulation testing in DIC is as follows:
(1) platelet count;
(2) PT/partial thromboplastin time/international normalized ratio (INR); (3) fibrinogen; (4) fibrinolysis markers: D-dimer (fibrin degradation products); (5) anticoagulant markers: protein C (PC) and antithrombin (AT) III; (6) fibrinolytic activity: plasminogen and alpha 2 antiplasmin; (7) antifibrinolytic activity: plasminogen activator inhibitor (PAI-l); (8) DIC markers: prothrombin activation fragment Fl þ 2, factor nine (FIX), and factor ten (FX) activation peptides; and (9) composite scoring systems.
Whole-blood viscoelastic testing
Theoretically, viscoelastic measurements of whole blood should provide clinicians with insight into in-vivo coagulation. Used in a serial fashion, the evolution of coagulopathy in septic patients could be identified and used to guide therapy. Ideally, it could provide prognostic value for patients with sepsis who are at risk for developing MODS. Unfortunately, the quality of evidence supporting thromboelastometry (TEM) in routine sepsis monitoring is low to moderate [9 & ]. In addition, studies using TEM in sepsis to determine proper therapy institution are lacking. Also, definitions for hypercoagulation and hypocoagulation are not standardized and internal validity of their use in clinical trials is often a concern [9 & ]. Concerning detection of coagulopathy in sepsis, a variety of studies showed heterogeneous results. Often when compared to CCTs and measured within the first 48 h, TEM measurements were within the normal ranges. Of note, patients who were deemed hypocoagulable (prolonged reaction time, reduced alpha angle, or deceased maximum amplitude) had increased mortality and were associated with DIC more often [9 & ]. In a study of 30 patients with severe
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sepsis followed over 2 days, patients with higher sequential organ failure assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHE) II scores had reduced maximum clot firmness and prolonged clot formation time [10] . TEM may serve as a beneficial negative predictor for developing coagulopathy.
Concerning the prognostic value of TEM in determining mortality in acute sepsis, early hypocoagulability was an independent risk factor for 28-day mortality in a series of severely septic patients [9 & ,11]. Adamzik compared the Simplified Acute Physiology Score II (SAPS II) and SOFA scores to rotational thromboelastometry (ROTEM) values, and found good correlation between these systems. In fact, pathologically altered values in ROTEM correlated with 58.7% 30-day survival versus 85.7% when all values were normal. In this study of 98 patients, ROTEM predicted survival better than the SAPS II and SOFA [12] . Ostrowski et al. [13 & ] used thromboelastography to monitor severely ill patients upon admission to the ICU. Patients were found to be hypocoagulable 22%, normal 48%, and hypercoagulable 30%. Patients who were hypocoagulable more often progressed to MODS and death. Patients who were normal upon admission and developed hypocoagulation had an 80% mortality rate. A key finding in most studies was that patients who were hypercoagulable or normal upon admission progressed to MODS and death less. This finding may allow for the stratification of patients who are at high risk of progressing to organ failure.
Platelet aggregometry offers another important viscoelastic measurement in sepsis. The test employs multiple platelet agonist and electrical impedance across coils to determine the platelet function in sampled whole blood. Brenner et al. [14] performed multiplate testing in 90 patients, comparing 30 severely septic patients to 30 postsurgical and 30 healthy patients. Septic patients displayed markedly reduced function to standard agonists compared with postsurgical and healthy volunteers. The effects of thrombocytopenia and dysfunction have been clearly illustrated in the critically ill population, significantly increasing mortality when dysfunction is prolonged over an ICU stay [15] .
Composite screening for coagulopathy in sepsis
Using combined data points to predict patients at risk for developing MODS from sepsis-induced coagulopathy is an area of interest in research. Diagnostic algorithms such as International Society on Thrombosis and Haemostasis DIC score, SAPS II, SOFA, and APACHE II combined with classical and viscoelastic measurements may provide the most accurate prognostic values [16] . A 2005 study using composite scoring for coagulopathy revealed an evolution of coagulation disturbances that occurs in the first 24 h of severe sepsis. Worsening coagulopathy in the first day was associated with greater 28-day mortality [5] . Koyama et al. [17] evaluated multiple plasma markers already evident in sepsis such as thrombin-antithrombin (TAT) complex, PC, and PAI-1 to estimate mortality and the development of overt DIC. When these plasma markers were combined, the area under the curve in selecting patients that would develop overt DIC was 0.95.
PATHOGENESIS OF THROMBUS FORMATION IN SEPSIS
Postmortem autopsies of patients with severe sepsis routinely show diffuse bleeding with microvascular thrombus formation and end-organ damage [18] . Animal studies utilizing endotoxemia have shown that it causes vascular fibrin deposition, resulting in organ failure. Blocking or reversing the coagulopathy in these animals has been shown to reverse organ dysfunction [19, 20] . Finally, clinical outcome studies with patients diagnosed with DIC reveal increased mortality, suggesting that prevention of DIC is a key therapeutic target [21] .
Procoagulant upregulation
The host inflammatory response to an invading organism rapidly initiates a procoagulant state in the septic patient. Thrombin generation is detectable within a few hours in models in which tumor necrosis factor and endotoxin were infused into humans [22, 23] . Additionally, endothelial injury that impairs the key anticoagulant mechanisms is observed within 15 min of lipopolysaccharide (LPS) infusion in rabbits [24] .
Key in the development of this procoagulant state is the interaction between tissue factor and inflammatory cytokine release. Tissue factor expression appears to be the initiating event in CAS. Tissue factor is responsible for binding and activating Factor VII on cell surfaces, thereby forming the enzyme-cofactor complex that results in amplified production of Factor Xa. Not only is tissue factor increased early in septic patients, but also impairment of the tissue factor pathway prevents coagulation abnormalities in animals [25, 26] . Debate over the primary source of tissue factor is ongoing as many cell types are capable of expressing tissue factor. Endothelial cells and mononuclear phagocytes such as monocytes and macrophages can express tissue factor, as can lung, kidney, and brain astrocytes [27] . Monocyte microparticles expressing tissue factor in mice have also been shown to activate the coagulation system [28] . Proinflammatory cytokines such as tumor necrosis factor (TNF), IL-1, and IL-6 are upregulated after tissue factor expression and play a major role in natural anticoagulant suppression and endothelial damage [29] .
Next, platelet-activating factor (PAF) is directly released secondary to inflammation [30] . Platelet activation results in several accelerators of thrombosis. First, platelet P-selectin expression results in increased monocyte tissue factor expression and platelet adhesion to leukocytes and endothelium [31, 32] . Once adhered to leukocytes and endothelium, platelets serve as a surface for thrombin generation and cellular signaling of other coagulation factors [8] .
Anticoagulant impairment
The impairment of three endogenous anticoagulants is evident in severe sepsis and contributes to hypercoagulopathy in the early inflammatory stage ( Fig. 1 ).
Tissue factor pathway inhibitor (TFPI) is an early regulator of the coagulation pathway that is activated by tissue factor and FVIIa interaction. TFPI (previously known as extrinsic pathway inhibitor) acts to prevent initial coagulation in two steps. First, TFPI binds to and inhibits FXa. Second, the TFPI-FXa complex binds to and inhibits tissue factor-FVIIa, thereby preventing early amplification of coagulation. TFPI is both consumed and degraded in sepsis leading to a procoagulant state [33] . TFPI is consumed quickly because of its relatively small concentration in plasma, approximately 1.0-2.5 nM [34] . Vascular endothelial cell expression of TFPI is also potentially degraded by plasmin, which is upregulated in early sepsis. This effect was demonstrated in baboons infused with Escherichia coli when TFPI activity was decreased coinciding with maximum TPA activity [35] .
Activated protein C (APC) is a potent anticoagulant that also has profibrinolytic and anti-inflammatory properties. Thus, APC derangement in sepsis significantly contributes to the early hypercoagulability. PC is activated by thrombin once bound to thrombomodulin. The endothelial PC receptor and cofactor protein S amplify its activation several fold [36] . Once activated, PC proteolytically cleaves Factors V and VII that are essential for the production of thrombin. PC synthesis is impaired, while consumption and degradation by neutrophil elastase further diminishes its concentration in plasma [29] . Next, thrombomodulin expression is drastically reduced by inflammatory cytokines such as TNFa, IL-1, and IL-6 [37] . Finally, endothelial protein C receptor (EPCR) is downregulated in severe sepsis, thereby limiting the activation of PC. Evidence also shows that because of endothelial damage, EPCR might be shed and not available for PC augmentation. This effect occurs as early as day 2 in severe sepsis [38] . The serine protease AT is a natural antagonist to thrombin that is activated several fold by circulating heparin-like substances. In severe sepsis, AT synthesis is downregulated and consumption is markedly increased because of ongoing thrombin formation [39] . In addition, membrane-bound, heparin-like glycosaminoglycans on the endothelial surface are reduced by the proinflammatory cytokines. This reduction further limits the bioactivity of AT [40] .
Resistance to fibrinolysis
In healthy human volunteers, the infusion of endotoxin produced a predictable and rapid change in the coagulation system. First, within 120 min, inflammatory markers such as TNF and IL-6 rose with a concurrent rise in the plasminogen activators, indicating endothelial activation. Within 150 min, this was counteracted by an even greater and sustained rise in PAI, thus supporting clot longevity [23] . It appears that both activated endothelial cells and platelets can express PAI [41] . Finally, the reduction in APC because of reduced availability of thrombomodulin may also play a role in decreased fibrinolysis. Less APC is available to inhibit PAI, thus augmenting clot stability [42 & ]. Thrombin induces the formation of thrombinactivatable fibrinolysis inhibitor (TAFI), a protease enzyme that reduces clot permeability and increases clot firmness [43] . In sepsis, tissue-factor-mediated thrombin production and inflammation produces dense clots that are resistant to fibrinolysis. This is thought to be mediated by both TAFI and platelet polyphosphate secretion that makes TPA less effective [44, 45] . In addition, the secretion of neutrophil elastase degrades the fibrinolytic proteases, contributing to clot persistence. The production of such a tightly aggregated clot could be a mechanism of defense against bacterial secreted proteases that break down clot integrity and allow for dissemination [46 & ]. In patients with meningococcal infections, TAFI levels are markedly increased, correlate with disease severity, and is associated with higher mortality [33] .
Endothelial damage
The vascular endothelium is an important regulator of hemostasis and a site of cellular interaction for immune cells. Endothelial cells (EC) mediate proinflammatory and anti-inflammatory mechanisms, regulate fibrinolysis, regulate vasomotor tone, and have immune cell signaling capabilities [47] . Thus, the endothelium acts as an important barrier for host defense in bacterial invasion. The surface layer of endothelial cells is a negatively charged, microthin layer of glycosaminoglycans and glycoproteins called the 'glycocalyx'. The intact glycocalyx repels the circulating platelets and acts as an anticoagulant layer because of its rich supply of heparin sulfates [47] . Ideally, the endothelium can balance the procoagulant and anticoagulant mechanisms after injury, thereby opposing thrombin generation when vascular repair is complete. However, when local injury becomes systemic, as in sepsis, the balance shifts toward a procoagulant state [48] .
Increased vascular permeability secondary to inflammation is a hallmark of sepsis and contributes significantly to organ dysfunction and possibly coagulation disturbances. As inflammation and coagulation are closely tied, therapies involved in endothelial protection may benefit coagulation abnormalities. Table 1 lists the multiple mechanisms that are implicated in endothelial damage, leading to increased permeability [48, 49, 50 && , 51,52].
The early shift toward a procoagulant state in sepsis is mediated by the proinflammatory markers that result in decreased expression of membranebound proteins such as thrombomodulin [53] . Endothelial injury also causes shedding and decreased expression of EPCR [38, 54] . The downregulating effect of this on the PC pathway has been described earlier. Endothelial cellular apoptosis resulting from LPS or endotoxin causes intracellular histone release that exacerbates inflammation and induces thrombosis. Endothelial disruption in inflammatory syndromes such as sepsis results in rapid platelet adhesion that can lead to microvascular thrombosis [50 && ]. Cumulatively, destruction of the endothelial cell layer importantly contributes to early coagulopathy in sepsis.
DISSEMINATED INTRAVASCULAR COAGULATION
Clinically, DIC is defined as simultaneous diffuse thrombosis and bleeding. Consumption of clotting factors because of ongoing thrombosis eventually leads to a hypocoagulable state. Relevant coagulation abnormalities are present in 50-70% of patients with severe infection, whereas about 35% of patients will actually meet the criteria for DIC [55] . The hallmark for treating DIC remains to eradicate the underlying cause of disease and support coagulation derangements as they occur. The manifestations of DIC though must still be addressed quickly, as the mortality associated with this grave diagnosis is high. Diagnostic criteria for DIC have been developed that employ common laboratory and clinical criteria. The criteria can be used clinically to distinguish overt DIC with diffuse bleeding and nonovert DIC, in which anticoagulation therapy could be useful [4] .
PATHOGENESIS OF MULTISYSTEM ORGAN DYSFUNCTION
Severe sepsis-associated organ dysfunction occurs because of multiple interactions between the proinflammatory state and hypercoagulation. The role of DIC as a causative factor in MODS is well supported. Alternatively, recent work has led to our understanding of other mediators of MODS, namely the effect of necrotic and apoptotic cellular release of intracellular proteins. High-mobility group box 1 (HMGB-1) proteins originate from dying cells, are released into the host circulation causing systemic inflammation, and propagate thrombosis [56] . Macrophages, endothelial cells, and monocytes are all capable of releasing HMGB-1 proteins. These cytokine-activating proteins are persistently elevated in septic patients and are associated with lethality in mice models [56] . Other intracellular released proteins such as histones associated with neutrophil extracellular traps (NETs) are highly toxic to organs, induce inflammation, and promote thrombosis [32, 57, 58] . NETs are cast by inflammatory cytokines and platelet activation, and comprise histonerich DNA fibers and antimicrobial proteins [58] . Histones (H3 and H4) induced thrombin generation by multiple mechanisms. First, extracellular histones dose dependently impair thrombomodulin activation of PC, thereby reducing the natural anticoagulant APC and eliminating its anti-inflammatory properties [57] . Secondly, thrombin production was increased by histone-mediated platelet activation and P-selectin expression. P-selectin expression increases the platelet adhesion to endothelial cells and leukocytes [32] . Thus, HMGB-1 and histone release into the circulation augment inflammation and thrombosis, promote cellular death, and potentiate MODS [33] .
THROMBOSIS AS A PROTECTIVE MECHANISM IN SEPSIS
Our understanding of thrombosis and inflammation in sepsis has evolved over decades of animal and human research. A key to understanding our early misconception of sepsis lies in how early animal studies were conducted. Commonly, models of mice employed intravenous administration of endotoxin or LPS or even live bacteria such as E. coli. Models of LPS and endotoxin infusion tended to uniformly overestimate the proinflammatory response in the host [59, 60] . Thus, early efforts targeted inflammation alone as a mediator of sepsis and were unsuccessful in the clinical setting. Likewise, universally inhibiting the coagulation system had deleterious effects as evidenced by the higher mortality rate of patients that were hypocoagulable upon ICU admission and higher bleeding tendencies [61] . These strategies ignored the protective mechanism of compartmentalization. Compartmentalization involves the acute-phase interaction of the proinflammatory response to elicit coagulation in an attempt to sequester bacteria or invading organisms. Acute-phase proteins such as fibrinogen and Factor V increase rapidly in acute sepsis augmenting the hypercoagulable response [55, 62] . Simultaneously, two powerful natural anticoagulants, PC and AT are downregulated. PC and AT could be viewed as negative acute-phase proteins in this protective early mechanism [63, 64] . Today's model of sepsis is viewed as both proinflammatory and anti-inflammatory or mixed anti-inflammatory response syndrome (MARS).
THERAPIES DIRECTED TOWARD MEDIATORS OF SEPSIS
Therapies directed toward the CAS should ideally restore the balance of inflammation and coagulation without negatively influencing the host's response to infection. Several trials have failed to recognize inflammation as an important protective mechanism or used uniform therapy for patients in different stages of sepsis. Antibodies directed toward TNFa, IL-1 receptors, and endotoxin failed to demonstrate a reduction in mortality [65] [66] [67] [68] . The failure of anticoagulant trials to show efficacy may be because of the inclusion of patients without DIC, uncertainty when to initiate treatment, and the tendency to underestimate the importance of bleeding [69] . This exemplifies the importance of developing specific diagnostic criteria for DIC that employs composite scoring systems, advanced markers for DIC, and TEM.
Tissue factor pathway inhibitor
As described earlier, TFPI is rapidly consumed in sepsis. Earlier studies on the efficacy of TFPI replacement demonstrated that in patients with INR greater than 1.2, mortality was not changed and adverse bleeding events were increased [70] . However, subgroup analysis of this study did show that in patients with community-acquired pneumonia (CAP), there was a trend toward survival. In 2011, Wunderink et al. [71] published the results of a large placebo-controlled study in patients with CAP treated with recombinant TFPI and again found no survival benefit though biological activity in improving coagulation parameters was evident.
Antithrombin
AT inhibits thrombin in a 1 : 1 manner and is maximally activated after interaction with receptors on the endothelial surface [72] . AT has anti-inflammatory properties through its inhibition of thrombin-Factor X, a complex that stimulates IL-1 and IL-6.
Recently, the Japanese Association of Acute Medicine DIC Committee evaluated AT use in a prospective RCT. Patients with DIC treated with AT over 3 days had faster recovery determined by DIC scores and did not have increased bleeding events [73] . In a nonrandomized larger study, Iba et al. determined that in patients with low baseline AT activity and sepsis, high-dose AT therapy 3000 IU/day (AT3000) was associated with improved survival (AT1500 65.2%, AT3000 74.7%) [74] . Importantly, these studies used DIC scoring systems to determine overt DIC and proper timing of anticoagulation therapy.
Activated protein C
It has been recognized for several years that a rapid decline in PC occurs in sepsis and that low levels of PC correlate with poor prognosis [26] . Also, hospital mortality was significantly reduced in patients who displayed multiorgan failure versus single-organ failure (OR 0.82 versus 0.78). A metaanalysis performed by Kalil in 2012 showed mortality benefit in patients with higher disease severity, but higher rates of adverse bleeding than were reported in the PROWESS trial. The results of this study indicated that rAPC could be beneficial in properly selected populations of septic patients.
Thrombomodulin
Thrombomodulin (CD141) is an endothelial transmembrane glycoprotein that has several regulatory functions in hemostasis. By binding thrombin, it prevents fibrinogen conversion to fibrin and prevents thrombin from interacting with platelets. The thrombin-thrombomodulin complex activates PC, resulting in a 100-fold increase in activity [53] . infection, the rate of DIC resolution was 66.1% with ART-123 versus 49.9% with heparin [78] . In this study, a statistically significant lower rate of adverse bleeding events with ART-123 was noticed. In another study of 86 patients with sepsis-induced DIC, mortality was lower and improved SOFA scores were associated with infusion of rTM versus those not treated with rTM (37 versus 58%, P ¼ 0.038) [79] . This was confirmed later in a study of 750 patients with sepsis and DIC, in which patients treated with ART-123 were associated with improved 28-day mortality [80] . Determining the optimal timing for treatment will be important for this promising DIC treatment.
Apoptosis
Model studies of septic mice treated with IL-7 have demonstrated benefit in reducing apoptosis of important CD4 and CD8 T-cells and improved immune function. IL-7 appears to have antiapoptotic functions essential to leukocyte survival [81, 82] . Targeting programmed cell death may have an important role in decreasing the inflammatory histones and HMGB-1 that are released into the systemic vasculature of septic patients [83, 84] . Immunomodulation studies such as this reinforce the intimate tie between coagulation and inflammation.
CONCLUSION
The host defense to infectious invasion is a highly regulated process involving inflammatory and antiinflammatory processes. In an attempt to compartmentalize invasion, the host creates hemostatic thrombin barriers and dense fibrin networks. Pathologically, these fibrin depositions can result in microvascular thrombus and result in end-organ ischemia. Establishing an operational definition of sepsis and DIC that is heralded by biological markers is the first step in constructing new therapeutic trials. Finally, we must improve patient stratification and staging to determine the optimal timing of interventions [85 & ].
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